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Summary
To present our results from 2018 and 2019 and to present the clinical data of the accuracy and clinical usefulness of 
computed tomography (CT)-guided biopsy for diagnosing suspicious bone lesion. The retrospective study included 98 
consecutive patients who underwent CT-guided bone lesion biopsy from January 2018 to December 2019. The localization 
of the bone lesions, the adequacy of the sample for histopathological analysis, histopathological results, and the procedure’s 
complications were analyzed. The specimens collected from 76 patients/lesions (77.6%) were considered appropriate for 
diagnosis. Histological analysis of bone samples showed 52 (68.4%) metastatic lesions. The most common primary tumor 
origins were breast carcinoma 28 (53.8%) and lung carcinoma six (11.5%). In three patients (4%), the infection was confirmed. 
no tumor cells were found in 17 (22.4%) patients. There were no post-procedural complications. CT-guided bone lesion 
biopsy is a safe and effective method for diagnosing suspicious bone lesions that has a great effect in clinical practice without 
any significant complications.
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INTRODUCTION
a CT-guided percutaneous biopsy is a pow-
erful tool in the evaluation of the bone lesions sus-
picious of malignancy. Bone metastases and sus-
picious primary bone tumors constitute frequent 
indications for CT-guided biopsy. The approach 
to a lesion as recurrence of a known malignant tu-
mor without histopathological confirmation may 
lead to inappropriate treatment of benign disease 
or incorrect management of a second primary tu-
mor different from the first one. In suspicious met-
astatic breast cancer cases, bone lesion biopsies 
are very valuable because of receptor conversion 
in metastatic breast cancer.
The CT-guided biopsy is a safe and accurate 
method to define the diagnosis of suspicious ra-
diologically detected bone lesion (1 - 4). a success-
ful bone biopsy is defined as a procedure that gets 
enough material for an appropriate histopatho-
logical analysis. The rate of successful percutane-
ous bone biopsies of the musculoskeletal lesion is 
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69 - 93% in the literature. (5-10). The rate of com-
plications in CT-guided bone biopsies is very low 
(1.1%), while in surgical (open) biopsies, it may be 
as high as 16% (11). This retrospective study aimed 
to determine the diagnostic definition and compli-
cations of CT-guided bone lesion biopsies.
MATERIALS AND METHODS
The retrospective study included 98 consecu-
tive patients who underwent CT-guided bone le-
sion biopsy between January 2018 and December 
2019 at the University Hospital Center Zagreb. Be-
fore the procedure, imaging data were reviewed 
in order to plan a safe and effective biopsy. Before 
the biopsy, the patient’s laboratory results (such 
as platelet count and prothrombin time) were re-
viewed.
The patient positioning on the CT table for 
biopsy was based on the targeted bone lesion’s lo-
cation. The selected site was confirmed by 6.0 mm 
thick CT sections, and a single section of the lesion 
was selected. The lesion approach was determined 
to avoid passing through more than one anatomi-
cal compartment and neurovascular structures. 
The spatial localization of the lesion and the cor-
relation with the grid was determined (figure 1). 
36 (36.7%) patients were under deep sedation, and 
62 (63.3%) patients were under local anesthesia. 
The specimens were collected with 9, 11, and 13 
gauge needles. from 1 to 4 core samples were col-
lected for histological analysis depending on the 
macroscopic appearance of the specimens and le-
sion localization and size. specimens were sub-
mitted in 10% formalin.
localization of the bone lesion, the sample’s 
adequacy for histopathological analysis, histo-
pathological results, and the procedure’s compli-
cations were analyzed.
RESULTS
in frequency order, involved bones were the 
following: 44 (44.9%) iliac bone, 10 (10.2%) verte-
brae, sacrum 9 (9.2%), sternum 8 (8.2%), femur 8 
(8.2%), pubic bone 5 (5.1%), tibia 4 (4.1%), scapula 
3 (3.1%), rib 2 (2%), acetabulum 2 (2%), humerus 2 
(2%), medial cuneiform bone 1 (1%). The speci-
mens collected from 76 lesions (77.6%) were con-
sidered appropriate for diagnosis. in 22 (22.4%) 
lesions specimens were not adequate, of which 2 
(9.1%) were blood clots, one (4.5%) was necrosis, 
19 (86.4%) were suboptimal sized samples for 
 definitive pathohistological analysis. In 56 cases 
(73.7%) metastatic lesions were confirmed and 
the primary tumor origins were the following: 28 
(53.8%) breast carcinoma, unknown origin 9 (17.3%), 
lung carcinoma 6 (11.5%), lower gastrointestinal 
tract carcinoma 1 (2%), kidney carcinoma 1 (2%), 
colon carcinoma 1 (2%), pancreatic carcinoma 1 
(2%), stomach carcinoma 1 (2%), prostatic carci-
noma 1 (2%), urothelial carcinoma 1 (2%) and sar-
coma 1 (2%). in 1 case (2%) metastatic bone lesion 
of neuroendocrine tumor was confirmed. In 3 pa-
tients (4%) infection was confirmed. Plasmacyto-
ma was confirmed in 3 (4%) patients and non-
Hodgkin lymphoma in 1 (1.3%) patient.
no tumor cells were found in 17 (22.4%) pa-
tients. There were no post-procedural complica-
tions.
Figure 1. CT-guided percutaneous bone biopsy. A: Planning pelvic CT with the grid (star) demonstrates a lytic lesion in the left iliac 
bone (white arrow). B: Needle positioned within the target lesion (black arrow). C: Post-biopsy follow-up with no immediate complica-





CT-guided bone biopsy is a safe, accurate, 
and minimally invasive procedure for diagnosing 
radiologically detected suspicious bone lesions. it 
has a significant impact on the management of on-
cologic patients. in our study, the main indication 
for biopsy was the analysis of a suspicious meta-
static lesion. even in patients with a known pri-
mary tumor and suspicious bone lesion, whose 
chance of a diagnosis different from metastasis is 
low, the confirmation of the diagnosis is required 
because it can influence these patients’ manage-
ment and prognosis, especially for the patients 
with breast cancer.
This study’s results have demonstrated that 
77.6% of CT-guided bone lesion biopsy specimens 
were sufficient for histopathological analysis, 
which is in concordance with the reported rate of 
successful percutaneous bone biopsies of muscu-
loskeletal lesion ranging from 69 to 93% (5-10).
We propose several potential reasons for a 
failed CT-guided bone biopsies; a failure in per-
forming a biopsy of the target lesion, failure in col-
lecting material sufficient for analysis or presence 
of necrosis in the specimens, impossibility of mak-
ing a definite diagnosis based on nonspecific his-
tological characteristics, and lack of confidence in 
results, requiring a new collection of specimen. 
Avoiding areas of necrosis correlates with a better 
rate of successful biopsies.
The procedure’s guidance with other imag-
ing methods may also be useful, for example, se-
lecting as a target those areas with more signifi-
cant metabolic activity at positron emission to-
mography with computed tomography (peT/CT) 
images (12-13). also, collecting a greater number 
of specimens when possible is recommended. The 
rate of complications observed in the present 
study was zero and compatible with data in the 
literature. The rate of complications in CT-guided 
bone biopsies is very low (1.1%), while in surgical 
(open) biopsies, it may be as high as 16% (1). Based 
on our data, we can conclude that CT-guided bone 
lesion biopsy is a safe and effective method used 
as a gold standard for sampling bone lesions sus-
picious for malignancy.
CONCLUSION
CT-guided bone lesion biopsy is a safe and 
effective method for diagnosing suspicious bone 
lesions that significantly affects clinical practice 
without any significant complication.
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BiopsiJe KoŠTaniH leZiJa poD KonTroloM CT-a, naŠa isKUsTVa iZ 2018. i 2019.
E. Krešić, A. Marija Alduk, M. Prutki, I. Karlak, K. Bolanča Čulo i M. Čavka
Cilj rada je predstaviti naše rezultate iz 2018. i 2019. i dodati saznanja kliničkim podatcima o točnosti i kliničkoj kori-
snosti biopsije vođene kompjuteriziranom tomografijom kod dijagnosticiranja suspektnih koštanih lezija. retrospektivno 
istraživanje obuhvatilo je 98 uzastopnih bolesnika koji su podvrgnuti biopsiji koštanih lezija pod kontrolom CT-a od siječnja 
2018. do prosinca 2019. analizirani su lokalizacija koštanih lezija, adekvatnost uzorka za patohistološku analizu, patohisto-
loški rezultati i komplikacije postupka. Uzorci prikupljeni od 76 pacijentata iz 76 lezija (77,6%) smatrani su prikladnima za 
dijagnozu. Histološka analiza uzoraka kostiju pokazala je 52 (68,4%) presadničke lezije. Najčešći izvor primarnog tumora 
bio je rak dojke 28 (53,8%), a rak pluća 6 (11,5%). U 3 bolesnika (4%) potvrđena je infekcija. U 17 (22,4%) bolesnika nisu pro-
nađene tumorske stanice. Biopsija koštanih oštećenja pod kontrolom CT-a sigurna je i učinkovita metoda bez ozbiljnijih 
komplikacija.
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